2306 GMT - ResMed's 12% on-year growth in December-quarter U.S. device sales is early evidence of the positive impact that tech wearables and weight-loss drugs are having on awareness of sleep apnea, Goldman Sachs analyst Davin Thillainathan says. He tells clients in a note that this awareness is translating into demand for ResMed's breathing-tech products. Thillainathan sees the result highlighting the defensiveness of ResMed's existing patient cohort against a backdrop of rising GLP-1 drug usage. GS lifts its target price by 0.2% to A$49.00 and keeps a buy rating on the stock. Shares are at A$40.18 ahead of the open. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 02, 2025 18:06 ET (23:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.